Pozaniklin

Из Википедије, слободне енциклопедије
Pozaniklin
(IUPAC) ime
2-metil-3-([(2S)-pirolidin-2-il]metoksi)piridin
Klinički podaci
Identifikatori
CAS broj 161417-03-4
ATC kod nije dodeljen
PubChem[1][2] 178052
UNII CL2002R563 YesY
Hemijski podaci
Formula C11H16N2O 
Mol. masa 192,258
SMILES eMolekuli & PubHem
Farmakoinformacioni podaci
Trudnoća  ?
Pravni status

Pozaniklin (ABT-089) je lek koji je razvilo preduzeće Abbott. On je parcijalni agonist neuronskih nikotinskih acetilholinskih receptora. Pozaniklin je selektivan za podtove α4β2 i α6β2.[3][4] Ovaj ligand ima nootropna i neuroprotektivna svojstva.[5][6][7] Životinjske studije sugerišu da on može da bude koristan u lečenju ADHD.[8]

Reference[уреди]

  1. ^ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.“. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519.  edit
  2. ^ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities“. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1. 
  3. ^ Marks MJ, Wageman CR, Grady SR, Gopalakrishnan M, Briggs CA (May 2009). „Selectivity of ABT-089 for alpha4beta2* and alpha6beta2* nicotinic acetylcholine receptors in brain“. Biochemical Pharmacology 78 (7): 795–802. DOI:10.1016/j.bcp.2009.05.022. PMC 2772152. PMID 19481067. 
  4. ^ Anderson DJ, Malysz J, Grønlien JH, El Kouhen R, Håkerud M, Wetterstrand C, Briggs CA, Gopalakrishnan M (June 2009). „Stimulation of dopamine release by nicotinic acetylcholine receptor ligands in rat brain slices correlates with the profile of high, but not low, sensitivity alpha4beta2 subunit combination“. Biochemical Pharmacology 78 (7): 844–51. DOI:10.1016/j.bcp.2009.06.024. PMID 19555668. 
  5. ^ Lin NH, Gunn DE, Ryther KB, Garvey DS, Donnelly-Roberts DL, Decker MW, Brioni JD, Buckley MJ, Rodrigues AD, Marsh KG, Anderson DJ, Buccafusco JJ, Prendergast MA, Sullivan JP, Williams M, Arneric SP, Holladay MW. Structure-activity studies on 2-methyl-3-(2(S)-pyrrolidinylmethoxy) pyridine (ABT-089): an orally bioavailable 3-pyridyl ether nicotinic acetylcholine receptor ligand with cognition-enhancing properties. Journal of Medicinal Chemistry. 1997 Jan 31;40(3):385-90. PMID 9022806
  6. ^ Sullivan JP, Donnelly-Roberts D, Briggs CA, Anderson DJ, Gopalakrishnan M, Xue IC, Piattoni-Kaplan M, Molinari E, Campbell JE, McKenna DG, Gunn DE, Lin NH, Ryther KB, He Y, Holladay MW, Wonnacott S, Williams M, Arneric SP. ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine]: I. A potent and selective cholinergic channel modulator with neuroprotective properties. Journal of Pharmacology and Experimental Therapeutics. 1997 Oct;283(1):235-46. PMID 9336329
  7. ^ Decker MW, Bannon AW, Curzon P, Gunther KL, Brioni JD, Holladay MW, Lin NH, Li Y, Daanen JF, Buccafusco JJ, Prendergast MA, Jackson WJ, Arneric SP. ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine dihydrochloride]: II. A novel cholinergic channel modulator with effects on cognitive performance in rats and monkeys. Journal of Pharmacology and Experimental Therapeutics. 1997 Oct;283(1):247-58. PMID 9336330
  8. ^ Prendergast MA, Jackson WJ, Terry AV Jr, Decker MW, Arneric SP, Buccafusco JJ. Central nicotinic receptor agonists ABT-418, ABT-089, and (-)-nicotine reduce distractibility in adult monkeys. Psychopharmacology (Berlin). 1998 Mar;136(1):50-8. PMID 9537682

Spoljašnje veze[уреди]